Drug Repurposing Studies
Genetic evidence de-risks drug development. Targets with human genetic support are twice as likely to succeed in clinical trials. Our repurposing analyses proxy drug action using genetic variants near or within drug target genes to predict efficacy and safety in new indications.
- Genetic proxy design using target cis-pQTLs and coding variants
- Indication scoring across disease GWAS catalogue
- Safety signal identification via phenome-wide scan
- Benchmarking against known drug-indication pairs
- Commercially actionable prioritisation reports with confidence tiers
Colocalization Outcomes
01.
Tier 1 — Strong
Colocalized pQTL MR + phenome-wide support + prior biological plausibility
02.
Tier 2 — Moderate
MR causal signal without colocalization confirmation; or indirect target evidence
03.
Tier 3 — Exploratory
Weaker genetic instruments or nominally significant MR — hypothesis generating
04.
Safety Flag
PheWAS signals suggesting unintended consequences of target modulation
